Colorectal

Most recent

Targeted Therapies in Metastatic Colorectal Cancer: An Update

NE Oncology Issue - June 2007 Meenakshi Kashyap Bevacizumab is effective in combination with XELOX or FOLFOX-4 Background Bevacizumab is a recombinant humanized monoclonal IgG1 antibody that inhibits the vascular endothelial growth factor (VEGF), an angiogenesis...

Canadian perspective by Dr. Cripps

NE Oncology Issue - June 2007 The updated results of the phase III trials comparing XELOX with FOLFOX-4 and FOLFOX-6 are very exciting. I use XELOX in my clinical practice and it is reassuring to see data that clearly demonstrate the equivalence of XELOX to FOLFOX-4...

Twitter feed

Dr. Irwindeep Sandhu provides an analysis of the TOURMALINE-MM3 study with post-ASCT patients receiving #ixazomib m… https://t.co/ll9s4q7vCL
h J R
Dr. Brian Leber discusses long-term follow-up of patients with #myelofibrosis treated with #JAK inhibitors #EHA2019… https://t.co/G4FuspL3NK
h J R
Dr. Darrell White writes about the impact of age on efficacy and safety from the MAIA trial in transplant-ineligibl… https://t.co/00XDPvNCVo
h J R
Dr. Irwindeep Sandhu talks about the importance of studying real-world Canadian data in #multiplemyeloma #EHA2019… https://t.co/WHNsd75EPZ
h J R
Dr. Brian Leber discusses a re-analysis of the JAKARTA-2 study in patients with myeloproliferative neoplasm-associa… https://t.co/GyZFmwk7sq
h J R

Other

Predictive value of skin toxicity and panitumumab efficacy

NE Oncology Issue - June 2007 Background Skin toxicities are a common side effect with EGFR inhibitor treatment. Results from the pivotal phase III trial for cetuximab indicate that there may be a physiologic correlation between the onset of skin toxicity and...

Canadian perspective by Dr. Cripps

NE Oncology Issue - June 2007 The data from the presentations at ASCO indicate that panitumumab is certainly very similar to cetuximab with regards to the efficacy and side effects profile. Panitumumab has the added advantage of slightly lower side effects and...

Targeted Therapy–Related Cutaneous Toxicities and their Treatment

NE Oncology Issue - June 2007 Arshia Tabassum Targeting the epidermal growth factor receptor: novel therapeutics in the management of cancer Overexpression of the epidermal growth factor receptor (EGFR) has frequently been correlated with a poor prognosis in...

Advances in the Treatment of Metastatic Colorectal Cancer

NE Oncology Issue - November 2006 Colorectal cancer (CRC) continues to be a leading cause of cancer morbidity and mortality worldwide. Over the last 50 years, the treatment of metastatic colorectal cancer (mCRC) has consisted of 5-fluorouracil (5-FU) -based...

Canadian Perspective by Dr. Sehdev

NE Oncology Issue - November 2006 The Roche-funded trial comparing XELOX to FOLFOX is the largest trial ever done for colorectal cancer, involving more than 2,000 patients in British and Spanish clinics. This is also the first data for first-line metastatic disease...

Twitter feed

Dr. Irwindeep Sandhu provides an analysis of the TOURMALINE-MM3 study with post-ASCT patients receiving #ixazomib m… https://t.co/ll9s4q7vCL
h J R
Dr. Brian Leber discusses long-term follow-up of patients with #myelofibrosis treated with #JAK inhibitors #EHA2019… https://t.co/G4FuspL3NK
h J R
Dr. Darrell White writes about the impact of age on efficacy and safety from the MAIA trial in transplant-ineligibl… https://t.co/00XDPvNCVo
h J R
Dr. Irwindeep Sandhu talks about the importance of studying real-world Canadian data in #multiplemyeloma #EHA2019… https://t.co/WHNsd75EPZ
h J R
Dr. Brian Leber discusses a re-analysis of the JAKARTA-2 study in patients with myeloproliferative neoplasm-associa… https://t.co/GyZFmwk7sq
h J R